Navigation Links
Liverpool receives $1.5M to tackle disease in Africa

A University of Liverpool-led consortium has received $1.5million from the Bill & Melinda Gates Foundation to study a bacterium that causes serious disease and epidemics in sub-Saharan Africa.

Streptococcus pneumoniae serotype1 is one of the most prevalent strains in sub-Sahara Africa. The funding will enable scientists to analyse the bacterium to determine why it is associated with invasive pneumococcal disease, why it spreads so quickly and why it has significant epidemic potential in some areas of Africa.

Invasive pneumococcal disease causes life-threatening pneumonia, meningitis and sepsis and is a major cause of death and serious illness in Africa. There are more than 90 different serotypes of Streptococcus pneumoniae - the bacterium that causes pneumococcal disease - but only a small number are associated with invasive pneumococcal disease.

Researchers based in Malawi, Nigeria, South Africa and The Gambia will analyse 300 wide-ranging and geographically relevant strains of Streptococcus pneumoniae serotype 1 to provide a detailed study of its genetic traits. The data will contribute to the current pneumococcal vaccine development programme led by PATH in the USA. In the longer term, the information will feed into the development of a protein-based vaccine that will enhance or replace current Pneumococcal Conjugate Vaccines (PCVs).

Vaccination provides the best form of protection against invasive pneumococcal disease. However, the vaccination programme that is being rolled out across Africa may not provide adequate protection against serotype 1. There are a number of PCVs currently available but none have shown a strong protective effect against serotype 1 and it is not known yet how the proposed PCVs which are due to be introduced to the programme will fare.

The project will also involve African researchers being trained to undertake the genomic-based research to enable local African researchers to process and analyse relevant data.

Dr Dean Everett, who is based in Malawi working as part of the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, said: "Streptococcus pneumoniae serotype 1 is one of the biggest causes of pneumococcal disease in sub-Sahara Africa and accounts for a quarter of infections in Malawi."

"Understanding the genetic traits that underpin serotype 1 and contribute towards its epidemic potential will help us to refine vaccine target discovery and guide the vaccine development process in order to provide better protection to those in sub-Saharan Africa where this serotype is most prevalent. This is an important first step in the process and importantly it will be driven by researchers in Africa."

Partners organisation involved in the consortium include: the University of Liverpool; the Malawi College of Medicine; Centre de Recherche Medicale et Sanitaire, Niger; National Health Laboratory Service, South Africa; Medical Research Council, The Gambia; the Wellcome Trust; the Liverpool School of Tropical Medicine; the London School of Tropical Medicine and Emory University in the USA.


Contact: Sarah Stamper
University of Liverpool

Related medicine news :

1. Case Western Reserve receives $10M to study retinal disease, develop new treatments
2. University of Houston receives $5 million grant from Houston Endowment
3. BMC radiologist receives 2010 Marie Sklodowska-Curie Award from AAWR
4. Dartmouth receives $2 million grant for childrens health research center
5. Harvard expert on inflammations role in obesity receives Columbias 2010 Naomi Berrie Award
6. Earl Smith receives Prentice Medal from American Academy of Optometry
7. Fred Hutchinson Cancer Research Center scientist receives Presidential Early Career Award
8. Miriam receives $1.5 million from NIH to seek, test and treat inmates with HIV
9. National Jewish Health receives patent for diagnostic method of autoimmune chronic urticaria
10. Breast center receives RI Pink Heals donation
11. UC San Diego receives 2 major biomedical informatics grants
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and ... diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians can ... from their electronic medical record (EMR) without the need for redundant patient entry ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ... These classically-influenced trailer titles work with any font, giving users limitless opportunities to ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
(Date:11/27/2015)... Nov. 26, 2015 ... of the "2016 Global Tumor Marker ... Volume and Sales Segment Forecasts, Innovative Technologies, ... report to their offering. --> ... the "2016 Global Tumor Marker Testing ...
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
Breaking Medicine Technology: